Focused Libraries for Epigenetic Drug Discovery: The Importance of Isosteres: Miniperspective
The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Abstract
Epigenetic drug discovery provides a wealth of opportunities for the discovery of new therapeutics but has been hampered by low hit rates, frequent identification of false-positives, and poor synthetic tractability. A key reason for this is that few screening collections consider the unique requirements of epigenetic targets despite significant medicinal chemistry interest. Here we analyze the suitability of some commercially available screening collections in the context of epigenetic drug discovery, with a particular focus on lysine post-translational modifications, and show that even privileged motifs found in U.S. Food and Drug Administration (FDA)-approved drugs are not present in these collections. We propose that the incorporation of epigenetic bioisosteres should become central in the design of new focused screening collections and highlight some opportunities for the development of synthetic methods which may improve the tractability of hit molecules.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Acetylated lysine drives the interactions, thus providing a starting point for molecular recognition and ligand development using acetylated lysine bio-isosteres [32].”
From Acetylation: a new target for protein degradation in cancer (2025) · cites this paper as [32]
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Jenuwein, T., & Allis, C. D. (2001) · Science · doi:10.1126/science.1063127 · Cited by 9,756
The molecular hallmarks of epigenetic control
Allis, C. D., & Jenuwein, T. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.59 · Cited by 2,809
The Medicinal Chemist’s Toolbox: An Analysis of Reactions Used in the Pursuit of Drug Candidates
Roughley, S. D., & Jordan, A. M. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200187y · Cited by 2,725
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
Brown, D. G., & Boström, J. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01409 · Cited by 1,964
An operational definition of epigenetics: Figure 1.
Berger, S. L., Kouzarides, T., Shiekhattar, R., & Shilatifard, A. (2009) · Genes & Development · doi:10.1101/gad.1787609 · Cited by 1,884
The medicinal chemist's toolbox for late stage functionalization of drug-like molecules
Cernak, T., Dykstra, K. D., Tyagarajan, S., Vachal, P., & Krska, S. W. (2016) · Chemical Society Reviews · doi:10.1039/c5cs00628g · Cited by 1,743
Organic synthesis provides opportunities to transform drug discovery
Blakemore, D. C., Castro, L., Churcher, I., Rees, D. C., Thomas, A. W., Wilson, D. M., & Wood, A. (2018) · Nature Chemistry · doi:10.1038/s41557-018-0021-z · Cited by 1,485
Taverna, S. D., Li, H., Ruthenburg, A. J., Allis, C. D., & Patel, D. J. (2007) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1338 · Cited by 1,418
Cancer Genetics and Epigenetics: Two Sides of the Same Coin?
You, J. S., & Jones, P. A. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.06.008 · Cited by 1,167
Rej, S., Ano, Y., & Chatani, N. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00495 · Cited by 996
Physiochemical drug properties associated with in vivo toxicological outcomes
Hughes, J. D., Blagg, J., Price, D. A., Bailey, S., DeCrescenzo, G. A., Devraj, R. V., Ellsworth, E., Fobian, Y. M., Gibbs, M. E., Gilles, R. W., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.071 · Cited by 946
The Age of Crosstalk: Phosphorylation, Ubiquitination, and Beyond
Hunter, T. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.11.019 · Cited by 942
Galloway, W. R. J. D., Isidro-Llobet, A., & Spring, D. R. (2010) · Nature Communications · doi:10.1038/ncomms1081 · Cited by 891
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours
Lasko, L. M., Jakob, C. G., Edalji, R. P., Qiu, W., Montgomery, D., Digiammarino, E. L., Hansen, T. M., Risi, R. M., Frey, R., Manaves, V., et al. (2017) · Nature · doi:10.1038/nature24028 · Cited by 858
Vemurafenib: the first drug approved for BRAF-mutant cancer
Bollag, G., Tsai, J., Zhang, J., Zhang, C., Ibrahim, P., Nolop, K., & Hirth, P. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3847 · Cited by 822
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells
Knutson, S. K., Wigle, T. J., Warholic, N. M., Sneeringer, C. J., Allain, C. J., Klaus, C. R., Sacks, J. D., Raimondi, A., Majer, C. R., Song, J., et al. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.1084 · Cited by 776
Expanding the medicinal chemistry synthetic toolbox
Boström, J., Brown, D. G., Young, R. J., & Keserü, G. M. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.116 · Cited by 665
Erlanson, D. A., McDowell, R. S., & O'Brien, T. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm040031v · Cited by 642
Deciphering the Transcriptional Histone Acetylation Code for a Human Gene
Agalioti, T., Chen, G., & Thanos, D. (2002) · Cell · doi:10.1016/s0092-8674(02)01077-2 · Cited by 638
Writers and Readers of Histone Acetylation: Structure, Mechanism, and Inhibition
Marmorstein, R., & Zhou, M.-M. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a018762 · Cited by 638
Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation
Qi, W., Chan, H., Teng, L., Li, L., Chuai, S., Zhang, R., Zeng, J., Li, M., Fan, H., Lin, Y., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1210371110 · Cited by 547
Wetzel, S., Bon, R. S., Kumar, K., & Waldmann, H. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201007004 · Cited by 505
Epigenetic Therapies for Cancer
Bates, S. E. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1805035 · Cited by 493
Schneider, N., Lowe, D. M., Sayle, R. A., Tarselli, M. A., & Landrum, G. A. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00153 · Cited by 427
Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation
Gilan, O., Rioja, I., Knezevic, K., Bell, M. J., Yeung, M. M., Harker, N. R., Lam, E. Y. N., Chung, C.-W., Bamborough, P., Petretich, M., et al. (2020) · Science · doi:10.1126/science.aaz8455 · Cited by 422
Structure and acetyl-lysine recognition of the bromodomain
Mujtaba, S., Zeng, L., & Zhou, M.-M. (2007) · Oncogene · doi:10.1038/sj.onc.1210618 · Cited by 421
Grant, S., Easley, C., & Kirkpatrick, P. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2227 · Cited by 412
Lead‐Oriented Synthesis: A New Opportunity for Synthetic Chemistry
Nadin, A., Hattotuwagama, C., & Churcher, I. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201105840 · Cited by 390
What Do Medicinal Chemists Actually Make? A 50-Year Retrospective
Walters, W. P., Green, J., Weiss, J. R., & Murcko, M. A. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200504p · Cited by 387
Beyond the Rule of 5: Lessons Learned from AbbVie’s Drugs and Compound Collection: Miniperspective
DeGoey, D. A., Chen, H.-J., Cox, P. B., & Wendt, M. D. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00717 · Cited by 378
Verma, S. K., Tian, X., LaFrance, L. V., Duquenne, C., Suarez, D. P., Newlander, K. A., Romeril, S. P., Burgess, J. L., Grant, S. W., Brackley, J. A., et al. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml3003346 · Cited by 371
NIH Molecular Libraries Initiative
Austin, C. P., Brady, L. S., Insel, T. R., & Collins, F. S. (2004) · Science · doi:10.1126/science.1105511 · Cited by 348
Inhibitors of histone acetyltransferases KAT6A/B induce senescence and arrest tumour growth
Baell, J. B., Leaver, D. J., Hermans, S. J., Kelly, G. L., Brennan, M. S., Downer, N. L., Nguyen, N., Wichmann, J., McRae, H. M., Yang, Y., et al. (2018) · Nature · doi:10.1038/s41586-018-0387-5 · Cited by 310
Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294
Chang, Y., Zhang, X., Horton, J. R., Upadhyay, A. K., Spannhoff, A., Liu, J., Snyder, J. P., Bedford, M. T., & Cheng, X. (2009) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1560 · Cited by 308
Mirguet, O., Gosmini, R., Toum, J., Clément, C. A., Barnathan, M., Brusq, J.-M., Mordaunt, J. E., Grimes, R. M., Crowe, M., Pineau, O., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401088k · Cited by 305
Cooper, T. W. J., Campbell, I. B., & Macdonald, S. J. F. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.201002238 · Cited by 299
3,5-Dimethylisoxazoles Act As Acetyl-lysine-mimetic Bromodomain Ligands
Hewings, D. S., Wang, M., Philpott, M., Fedorov, O., Uttarkar, S., Filippakopoulos, P., Picaud, S., Vuppusetty, C., Marsden, B., Knapp, S., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200640v · Cited by 216
Late-Stage Fluorination: From Fundamentals to Application
Campbell, M. G., & Ritter, T. (2014) · Organic Process Research & Development · doi:10.1021/op400349g · Cited by 212
Methot, J. L., Chakravarty, P. K., Chenard, M., Close, J., Cruz, J. C., Dahlberg, W. K., Fleming, J., Hamblett, C. L., Hamill, J. E., Harrington, P., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.12.031 · Cited by 191
Recent Progress in Histone Demethylase Inhibitors
McAllister, T. E., England, K. S., Hopkinson, R. J., Brennan, P. E., Kawamura, A., & Schofield, C. J. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01758 · Cited by 186
Monocyclic aromatic amines as potential human carcinogens: old is new again
Skipper, P. L., Kim, M. Y., Sun, H.-L. P., Wogan, G. N., & Tannenbaum, S. R. (2010) · Carcinogenesis · doi:10.1093/carcin/bgp267 · Cited by 183
Kinase hinge binding scaffolds and their hydrogen bond patterns
Xing, L., Klug-Mcleod, J., Rai, B., & Lunney, E. A. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.08.006 · Cited by 180
Molecular inflation, attrition and the rule of five
Leeson, P. D. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.01.018 · Cited by 179
Kuntz, K. W., Campbell, J. E., Keilhack, H., Pollock, R. M., Knutson, S. K., Porter-Scott, M., Richon, V. M., Sneeringer, C. J., Wigle, T. J., Allain, C. J., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01501 · Cited by 175
Small Molecule Inhibitors of Bromodomain–Acetyl-lysine Interactions
Brand, M., Measures, A. M., Wilson, B. G., Cortopassi, W. A., Alexander, R., Höss, M., Hewings, D. S., Rooney, T. P. C., Paton, R. S., & Conway, S. J. (2015) · ACS Chemical Biology · doi:10.1021/cb500996u · Cited by 172
Ma, B., Chu, Z., Huang, B., Liu, Z., Liu, L., & Zhang, J. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201611809 · Cited by 135
Tang, P., Zhang, J., Liu, J., Chiang, C.-M., & Ouyang, L. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01487 · Cited by 135
Dekker, F. J., van den Bosch, T., & Martin, N. I. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2013.11.012 · Cited by 132
Small-Molecule Modulators of Methyl-Lysine Binding for the CBX7 Chromodomain
Ren, C., Morohashi, K., Plotnikov, A. N., Jakoncic, J., Smith, S. G., Li, J., Zeng, L., Rodriguez, Y., Stojanoff, V., Walsh, M., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.11.021 · Cited by 127
Small-Molecule Ligands of Methyl-Lysine Binding Proteins
Herold, J. M., Wigle, T. J., Norris, J. L., Lam, R., Korboukh, V. K., Gao, C., Ingerman, L. A., Kireev, D. B., Senisterra, G., Vedadi, M., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200045v · Cited by 120
Phosphatidylinositol 3 kinase (PI3K) inhibitors as new weapon to combat cancer
Elmenier, F. M., Lasheen, D. S., & Abouzid, K. A. M. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111718 · Cited by 120
Assay interference and off-target liabilities of reported histone acetyltransferase inhibitors
Dahlin, J. L., Nelson, K. M., Strasser, J. M., Baršytė-Lovejoy, D., Szewczyk, M. M., Organ, S. L., Cuellar, M. E., Singh, G., Shrimp, J. H., Nguyen, N. H., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01657-3 · Cited by 113
Cancer's epigenetic drugs: where are they in the cancer medicines?
Ghasemi, S. (2019) · The Pharmacogenomics Journal · doi:10.1038/s41397-019-0138-5 · Cited by 110
Fragment-based discovery of a chemical probe for the PWWP1 domain of NSD3
Böttcher, J., Dilworth, D., Reiser, U., Neumüller, R. A., Schleicher, M., Petronczki, M. P., Zeeb, M., Mischerikow, N., Allali‐Hassani, A., Szewczyk, M. M., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0310-x · Cited by 109
Profiling and Application of Photoredox C(sp3)–C(sp2) Cross-Coupling in Medicinal Chemistry
Zhang, R., Li, G., Wismer, M. K., Váchal, P., Colletti, S. L., & Shi, Z. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00183 · Cited by 97
Wagner, F. F., Weïwer, M., Steinbacher, S., Schomburg, A., Reinemer, P., Gale, J. P., Campbell, A. J., Fisher, S. L., Zhao, W., Reis, S. A., et al. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.06.040 · Cited by 79
Small Molecules Targeting HATs, HDACs, and BRDs in Cancer Therapy
Wu, D., Qiu, Y., Jiao, Y., Qiu, Z., & Liu, D. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.560487 · Cited by 79
KATching-Up on Small Molecule Modulators of Lysine Acetyltransferases
Simon, R. P., Robaa, D., Alhalabi, Z., Sippl, W., & Jung, M. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01502 · Cited by 74
Ren, C., Smith, S. G., Yap, K. L., Li, S., Li, J., Mezei, M., Rodríguez, Y., Vincek, A. S., Aguiló, F., Walsh, M. J., et al. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00042 · Cited by 74
Development and evaluation of selective, reversible LSD1 inhibitors derived from fragments
Hitchin, J. R., Blagg, J., Burke, R., Burns, S., Cockerill, M. J., Fairweather, E. E., Hutton, C. P., Jordan, A. M., McAndrew, C., Mirza, A. R., et al. (2013) · MedChemComm · doi:10.1039/c3md00226h · Cited by 69
Discovery, design, and synthesis of indole-based EZH2 inhibitors
Gehling, V. S., Vaswani, R. G., Nasveschuk, C. G., Duplessis, M., Iyer, P., Balasubramanian, S., Zhao, F., Good, A. C., Campbell, R., Lee, C., et al. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.06.056 · Cited by 68
Foley, D. J., Craven, P. G. E., Collins, P. M., Doveston, R. G., Aimon, A., Talon, R., Churcher, I., von Delft, F., Marsden, S. P., & Nelson, A. S. (2017) · Chemistry - A European Journal · doi:10.1002/chem.201704169 · Cited by 68
The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells
Maharaj, K. K., Powers, J. J., Achille, A. N., Mediavilla-Varela, M., Gamal, W. M., Burger, K. L., Fonseca, R., Jiang, K., Miskin, H. P., Maryanski, D., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001800 · Cited by 64
Targets in Epigenetics: Inhibiting the Methyl Writers of the Histone Code
Yost, J. M., Korboukh, I., Liu, F., Gao, C., & Jin, J. (2011) · Current Chemical Genomics · doi:10.2174/1875397301005010072 · Cited by 61
Chemical Inhibitors of Epigenetic Methyllysine Reader Proteins
Milosevich, N., & Hof, F. A. (2015) · Biochemistry · doi:10.1021/acs.biochem.5b01073 · Cited by 58
Preston, A., Atkinson, S., Bamborough, P., Chung, C.-W., Craggs, P. D., Gordon, L., Grandi, P., Gray, J. R. J., Jones, E. J., Lindon, M., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00605 · Cited by 57
Plotnikov, A. N., Yang, S., Zhou, T., Rusinova, E. V., Frasca, A., & Zhou, M. (2013) · Structure · doi:10.1016/j.str.2013.10.021 · Cited by 54
Understanding the Complexity of Epigenetic Target Space
Pande, V. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01507 · Cited by 40
Small molecule epigenetic inhibitors targeted to histone lysine methyltransferases and demethylases
Wang, Z., & Patel, D. J. (2013) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583513000085 · Cited by 36
Aylott, H. E., Atkinson, S. J., Bamborough, P., Bassil, A. K., Chung, C., Gordon, L. J., Grandi, P., Gray, J. R., Harrison, L. A., Hayhow, T. G., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02156 · Cited by 35
Advances and Opportunities in Epigenetic Chemical Biology
Beyer, J. N., Raniszewski, N. R., & Burslem, G. M. (2020) · ChemBioChem · doi:10.1002/cbic.202000459 · Cited by 23
Self-citationThe therapeutic potential of acetyl-lysine and methyl-lysine effector domains
Brennan, P. E., Filippakopoulos, P., & Knapp, S. (2012) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2012.04.001 · Cited by 15
Tao, Q., Chen, Y., Liang, X. H., Hu, Y., Li, J., Fang, F., Wang, H., Meng, C., Liang, J., Ma, X., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112143 · Cited by 15
Cited by
Mao, L., Liu, Y., & Wan, J. (2024) · Chinese Chemical Letters · doi:10.1016/j.cclet.2024.110784 · Cited by 54
Drug discovery for epigenetics targets
Holdgate, G. A., Bardelle, C., Lanne, A., Read, J. A., O’Donovan, D. H., Smith, J. M., Selmi, N., & Sheppard, R. J. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.10.020 · Cited by 37
Song, S., Zhang, Z., Peng, M., Xia, X., Dong, S., Wang, Y., & Yu, F. (2024) · Organic Chemistry Frontiers · doi:10.1039/d4qo00677a · Cited by 29
Chemoinformatic Characterization of Synthetic Screening Libraries Focused on Epigenetic Targets
Flores‐Padilla, E. A., Juárez‐Mercado, K. E., Naveja, J. J., Kim, T. D., Miranda‐Quintana, R. A., & Medina‐Franco, J. L. (2021) · Molecular Informatics · doi:10.1002/minf.202100285 · Cited by 23
Acetylation: a new target for protein degradation in cancer
Crawford, C. E. W., & Burslem, G. M. (2025) · Trends in Cancer · doi:10.1016/j.trecan.2025.01.013 · Cited by 20
Self-citation
Metadata
- Authors
- Green, A. I., & Burslem, G. M.
- Affiliations
- University of Pennsylvania (US)
- Corresponding author
- Burslem, George M.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2021-05-27
- Volume
- 64
- Issue
- 11
- Pages
- 7231-7240
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W3164094558
- Cited by
- 21
- References
- 77
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 4 · 2023: 3 · 2022: 4 · 2021: 5
- FWCI
- 2.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- epigenetic drug discovery, focused libraries, isosteres, lysine post-translational modifications, hit optimization, privileged structures
- MeSH terms
- Biological Products, Humans, Protein Kinases, Protein Processing, Post-Translational, Small Molecule Libraries, Drug Discovery, Histone Demethylases, Epigenomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.